相关实验视频
Updated: May 9, 2025

10:28
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
Published on: May 24, 2018
15.3K
GIPR-Ab/GLP-1-抗体结合剂需要大脑GIPR和GLP-1R来增加肥胖小鼠的体重减轻
Clarissa M Liu1,2, Elizabeth A Killion1, Rola Hammoud3
1Department of Cardiometabolic Disorders, Amgen Research, Thousand Oaks, CA, USA.
Nature metabolism
|April 29, 2025
概括
中枢神经系统 (CNS) GIPR和GLP-1R信号传递对于双重GIPR阻断/GLP-1R激活抗体结合物的减肥效果至关重要. 这两种受体对于最大限度地提高肥胖治疗结果至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 神经科学是一个神经科学.
- 代谢疾病 代谢疾病
背景情况:
- 葡萄糖依赖性胰岛素型多受体 (GIPR) 和葡萄糖类1受体 (GLP-1R) 存在于中枢神经系统,影响食欲.
- 针对两种受体的双重作用药物对治疗肥胖有希望.
研究的目的:
- 调查中央神经系统 (CNS) GIPR和GLP-1R对于阻断GIPR/激活GLP-1R的抗体结合物的有效性 (GIPR-Ab/GLP-1) 的必要性.
- 阐明中枢神经系统受体在调节体重减轻和由双素受体调节诱导的代谢变化中的作用.
主要方法:
- 在肥胖小鼠模型中使用-抗体结合物 (GIPR-Ab/GLP-1),包括中枢神经系统GIPR淘汰赛 (KO) 的小鼠.
- 单独和组合使用杜拉格卢提德和GIPR-Ab/GLP-1.
- 在白色脂肪组织和肝脏中分析基因表达.
- 在大脑周腔器官中检测出结合物存在,并在神经通路中测量c-FOS激活.
主要成果:
- 使用GIPR-Ab/GLP-1的最大体重减轻需要中枢神经系统的GIPR和中枢神经系统的GLP-1R.
- 在中枢神经系统GIPR KO小鼠中,杜拉古胺诱导了更大的体重减轻;在中枢神经系统GIPR KO小鼠中,联合杜拉古胺+GIPR-Ab的疗效降低了.
- GIPR-Ab/GLP-1和中枢神经系统GIPR KO小鼠在代谢和炎症途径中表现出类似的基因表达变化.
- 结合物在周围腹膜器官中被发现,并激活了调节食欲的神经回路.
结论:
- 中枢神经系统的GIPR和GLP-1R信号通路对于GIPR-Ab/GLP-1结合物的完全减肥潜力是不可或缺的.
- 涉及食欲调节的中央机制是结合物的作用的关键调解者.
- 针对中枢神经系统中的双素受体,对肥胖管理具有显著的治疗前景.
更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
GPCRs Regulate Adenylyl Cylase Activity
5.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.0K
G Protein-coupled Receptors
10.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
10.6K
GPCR Desensitization
5.6K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.6K
Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109

